Background: Our goals were to demonstrate receptor binding domain spike 1 (RBD S1) protein antibody (Ab) kinetic responses to multiple vaccines over approximately 180 days, neutralizing Ab effectiveness, and high-sensitivity cardiac troponin I (hs-cTnI) and T (hs-cTnT) responses in postvaccinated, non-SARS-CoV-2-infected subjects.
Methods: Blood specimens were collected pre- and postvaccinations from seronegative subjects. RDB S1 Abs were measured by the novel Qorvo Biotechnologies Omnia platform. Neutralizing Abs and hs-cTnI and hs-cTnT were measured on the ET Healthcare Pylon 3D.
Results: Two-dose vaccines (Pfizer, Moderna) had peak RBD S1 Ab concentrations about 45 to 55 days after both doses and showed declines over the next 50 to 70 days. The Janssen vaccine showed lower RBD S1 Ab peak concentrations, continued to increase over time, and plateaued after 60 days. There was strong neutralizing Ab response post vaccinations, with only 3 specimens, shortly before and shortly after vaccination, not showing a response. Specimens showed no hs-cTnI (all < 3 ng/L) and hs-cTnT (all < 6 ng/L) increases or changes over time.
Conclusions: We demonstrate in seronegative SARS-CoV-2 subjects that Pfizer and Moderna vaccinations provide strong, neutralizing RBD S1 Ab effectiveness, based on 2 different assays after 2 doses, with the Janssen single-dose vaccine showing a lower RBD S1 Ab response over 4 to 6 months. No myocardial injury was associated with the Pfizer postvaccination. The Qorvo Biotechnologies RBD S1 Ab assay measured on the Omnia platform has potential as a point-of-care platform.
Competing Interests: Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest: Employment or Leadership: F.S. Apple, Clinical Chemistry, AACC; B. Bothwell, Qorvo; J. Koti, Qorvo; W. Bauer, Qorvo; R. Dwyer, Qorvo; H. Chen, ET Healthcare; P. Li, ET Healthcare; H. Wu, ET Healthcare. Consultant or Advisory Role: F.S. Apple, Consultant: HyTest Ltd, Advisory Boards: Werfen, Siemens Healthineers, Qorvo Biotechnologies. Stock Ownership: B. Bothwell, Qorvo; J. Koti, Qorvo; W. Bauer, Qorvo; R. Dwyer, Qorvo. Honoraria: F.S. Apple, Siemens Healthineers. Research Funding: F.S. Apple, PI on Industry Funded Grants (non-salaried) on cardiac biomarkers through Hennepin Healthcare Research Institute: Abbott Diagnostics, Abbott POC, BD, Beckman Coulter, Ortho-Clinical Diagnostics, Roche Diagnostics, Siemens Healthcare. Both ET Healthcare and Qorvo Biotechnologies supplied assay kits to the research institute for this study. Expert Testimony: None declared. Patents: None declared.
(© American Association for Clinical Chemistry 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)